Nama's AI scorecard currently rates Teleflex Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is TFX's P/E ratio?

Teleflex trades at a trailing price-to-earnings ratio of 19.6.

When does TFX report earnings?

Teleflex's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.96.

What is the TFX price target?

The median analyst price target from 11 analysts is $155.00, with a range of $138.00 – $170.00.

Is TFX Shariah compliant?

Nama's AAOIFI-style screen reads Teleflex as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does TFX pay a dividend?

Yes — Teleflex's dividend yield is 0.9%.

Nama Insights

Teleflex (TFX)

Healthcare · Medical Instruments Supplies · NYSE

Teleflex (TFX) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $6.39B, a trailing price-to-earnings ratio of 19.6 and a free-cash-flow yield of 3.6%. Over the most recent reported fiscal year, revenue grew 17.2% and free cash flow per share fell 52.6%. Nama's AI scorecard rates it Hold, 5.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.0/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +14.7% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-57.7%

How far the last close sits under the highest price of the past five years.

Market cap	$6.39B
Trailing P/E	19.6
Price / book	2.2
Price / sales	2.8
FCF yield	3.6%
Dividend yield	0.9%
Gross margin	57.6%
Operating margin	3.6%
Net margin	-63.3%
Revenue growth (YoY)	+17.2%
Revenue growth (3-yr annual)	-10.6%
EPS growth (YoY)	-12.6%
FCF/share growth (YoY)	-52.6%
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

TFX earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.96). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$2.63	$1.89	+39.1%	—
Q2 2026	Aug 6, 2026	$1.76	$1.28	+37.5%	$570.33M
Q1 2026	May 7, 2026	$1.39	$1.21	+14.9%	$548.26M
Q4 2025	Feb 26, 2026	$1.93	$3.75	-48.5%	-$401.87M

TFX analyst price target

Median target $155.00 from 11 analysts, ranging $138.00 – $170.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live TFX data on Nama Insights →

Recent Congressional trades

Teleflex trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Rob Bresnahan	House	Sell	$1,001 - $15,000	Mar 27, 2025
Daniel Goldman	House	Sell	$15,001 - $50,000	Aug 13, 2023
Susan M Collins	Senate	Buy	$15,001 - $50,000	—

TFX FAQ

Is TFX a buy?: Nama's AI scorecard currently rates Teleflex Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is TFX's P/E ratio?: Teleflex trades at a trailing price-to-earnings ratio of 19.6.
When does TFX report earnings?: Teleflex's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.96.
What is the TFX price target?: The median analyst price target from 11 analysts is $155.00, with a range of $138.00 – $170.00.
Is TFX Shariah compliant?: Nama's AAOIFI-style screen reads Teleflex as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does TFX pay a dividend?: Yes — Teleflex's dividend yield is 0.9%.